(VOR) Vor Biopharma - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 822m USD | Total Return: 283.2% in 12m
Avg Turnover: 11.9M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Altman Z'' -15.00 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
Leader, Confidence
Vor Biopharma Inc. is a Boston-based, clinical-stage biopharmaceutical company focused on developing therapies for autoimmune conditions. Its primary pipeline candidate, telitacicept, is a novel fusion protein currently under investigation for indications including generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. The company operates through a strategic licensing agreement with RemeGen Co., Ltd. to manage the commercialization and development of this asset.
The biotechnology sector often utilizes licensing agreements to mitigate the high capital expenditures and long lead times associated with clinical trials. Vor Biopharma’s business model relies on advancing these specialized protein therapies through the regulatory approval process to address chronic inflammatory diseases. Investors may find it useful to review ValueRay for further data on the companys valuation metrics. The success of such clinical-stage firms is typically contingent upon trial data outcomes and the strength of their intellectual property portfolios.
- Clinical trial data readouts for VOR33 in acute myeloid leukemia patients
- Regulatory approval milestones for proprietary eHSC and CAR-T combination therapies
- R&D expenditure and cash runway sustainability through upcoming clinical phases
- Strategic partnership developments and licensing agreements for telitacicept commercialization
- Competitive landscape shifts within the engineered hematopoietic stem cell therapy market
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.69 > 0.02 and ΔFCF/TA -70.78 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 > 3% & CFO -149.9m > Net Income -883.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 31.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (430k) vs 12m ago -93.11% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 3.37%; Δ -3.37% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.96 (Total Current Assets 500.8m - Total Current Liabilities 16.1m) / Total Assets 506.7m |
| B: -2.71 (Retained Earnings -1.37b / Total Assets 506.7m) |
| C: -3.66 (EBIT TTM -1.13b / Avg Total Assets 308.0m) |
| D: -2.09 (Book Value of Equity -1.37b / Total Liabilities 657.2m) |
| Altman-Z'' = -29.34 = D |
As of May 24, 2026, the stock is trading at USD 15.04 with a total of 1,039,186 shares traded.
Over the past week, the price has changed by -2.05%,
over one month by -6.46%,
over three months by -7.07% and
over the past year by +283.16%.
Vor Biopharma has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold VOR.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 37.9 | 151.9% |
Revenue TTM = 0.0 USD
EBIT TTM = -1.13b USD
EBITDA TTM = -1.13b USD
Long Term Debt = 2.63m USD (estimated: total debt 2.94m - short term 307k)
Short Term Debt = 307k USD (from shortTermDebt, last quarter)
Debt = 2.94m USD (from shortLongTermDebtTotal, last quarter) (leases 2.94m already included)
Net Debt = -488.6m USD (calculated: Debt 2.94m - CCE 491.5m)
Enterprise Value = 333.4m USD (822.0m + Debt 2.94m - CCE 491.5m)
Interest Coverage Ratio = unknown (Ebit TTM -1.13b / Interest Expense TTM 0.0)
EV/FCF = -0.39x (Enterprise Value 333.4m / FCF TTM -854.1m)
FCF Yield = -256.2% (FCF TTM -854.1m / Enterprise Value 333.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.66 (Enterprise Value 333.4m / Total Assets 506.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.94m)
Taxrate = 21.0% (US default 21%)
NOPAT = -890.6m (EBIT -1.13b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 29.25 (Total Current Assets 500.8m / Total Current Liabilities 17.1m)
Debt / Equity = -0.02 (negative equity) (Debt 2.94m / totalStockholderEquity, last quarter -150.4m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -488.6m / EBITDA -1.13b)
Debt / FCF = 0.57 (negative FCF - burning cash) (Net Debt -488.6m / FCF TTM -854.1m)
Total Stockholder Equity = -1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = -286.7% (out of range, set to none)
RoE = -244.6% (Net Income TTM -883.1m / Total Stockholder Equity 361.1m)
RoCE = -310.0% (out of range, set to none) (EBIT -1.13b / Capital Employed (Equity 361.1m + L.T.Debt 2.63m))
RoIC = -181.4% (out of range, set to none) (NOPAT -890.6m / Invested Capital 491.0m)
WACC = 10.61% (E(822.0m)/V(824.9m) * Re(10.65%) + D(2.94m)/V(824.9m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: -60.08%
[DCF] Fair Price = unknown (Cash Flow -854.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.00 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.70 | Chg30d=+12.41% | Revisions=+43% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.75 | Chg30d=+12.27% | Revisions=+43% | Analysts=3
EPS current Year (2026-12-31): EPS=-6.81 | Chg30d=-101.16% | Revisions=-33% | GrowthEPS=+90.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.60 | Chg30d=+2.90% | Revisions=+33% | GrowthEPS=+47.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +43%